Filing Flows › Zomedica (ZOMDF) › Q3 2026
Zomedica (ZOMDF) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Zomedica (ZOMDF) reported revenue of $9.9M for the third quarter 2026 (Q3 2026), +22% from a year earlier and +4% from the quarter before. Operating margin was -34.6%, net loss $3.2M (32.0% of revenue).
Zomedica, Q3 2026: revenue $9.9M (+22% year over year), operating margin -34.6%, net loss $3.2M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.9M | +4% | +22% |
| Operating profit | −$3.4M | — | — |
| Net earnings | −$3.2M | — | — |
| Operating cash flow | −$2.8M | — | — |
What changed
Revenue was $9.9M in Q3 2026, up 22% year over year and up 4% from the previous quarter. Consumables was the largest line at 69% of revenue. Consumables added $1.4M year over year (up 26%), 78% of the total change. Capital declined 9%.
Gross margin was 61.1%, down 6.1 points from Q3 2025. Operating costs exceeded revenue by $3.4M, an operating margin of -34.6%. Operating expenses fell 21% while revenue rose 22%. The quarter ended with a net loss of $3.2M, narrower than the previous quarter's $3.8M loss.
Operating cash flow was −$2.8M. Non-cash charges added back $1.8M of depreciation and amortization. Working capital and other items used $1.4M. Capital expenditures of $187K exceeded it, leaving free cash flow of −$3.0M.
Questions
What was Zomedica's revenue in the third quarter 2026?
Zomedica (ZOMDF) reported revenue of $9.9M for the third quarter 2026 (Q3 2026), +22% from a year earlier and +4% from the quarter before.
Was Zomedica profitable in the third quarter 2026?
Operating loss was $3.4M (-34.6% of revenue) and net loss $3.2M.
Source: Zomedica 10-Q on SEC EDGAR.